A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study
Introduction: Enarodustat (JTZ-951) is a new oral hypoxia-inducible factor-prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD). We conducted a phase 3 study to compare the efficacy and safety of enarodustat with darbepoetin alfa (DA) in Japanese anemic patients w...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2021-07-01
|
Series: | Kidney Diseases |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/517053 |